血亏200亿 “日本神药”要卖了
Quick Summary
Overall: This report centers on Kobayashi Pharmaceutical's massive losses, declining performance, and possible acquisition due to the red yeast rice supplement safety scandal. Ordinary consumers can draw several important reminders.
1. Red yeast rice supplements carry health risks: Starting in March 2024, some consumers who took Kobayashi's supplements containing red yeast rice developed kidney disease. By the end of August 2026, about 520 consumers had been certified for compensation, and the number of related deaths counted by Japan's Ministry of Health, Labour and Welfare once reached 81. When choosing supplements, consumers should not just look at marketing claims; they should also pay attention to ingredient safety and the company's quality record.
2. Acquisition and stock price changes: Private equity firms CVC and NSSK are considering acquiring Kobayashi for more than 500 billion yen (about 21.5 billion RMB). The news boosted the stock price by over 16% in one week, giving the company a market capitalization of about 534.6 billion yen, still roughly half of its peak of 1.07 trillion yen in 2020. Consumers can use these signals to judge whether a brand is operating steadily.
3. Even once best-selling products should be viewed rationally: Kobayashi became the "Japanese miracle drug" maker through analgesic anti-inflammatory agents, cooling sheets, deodorants, etc. But after the scandal, its operating profit for the first half of 2026 fell sharply by 67.5% year on year, showing that brand halo does not equal long-term safety. Consumers should remain cautious when buying Japanese drugstore and health products.
Overall: Kobayashi Pharmaceutical's trajectory from niche market champion to the trust crisis after the red yeast rice incident offers important operational lessons and strategic references for brand owners.
1. Fishing for big fish in a small pond: Kobayashi avoided the big pond of 10 billion yen where large companies compete fiercely, and instead selected small markets with a scale of 1 billion yen. Through niche products such as dental floss sticks, callus removers, and deodorants, it achieved high market share and high profit margins, and built distinctiveness with eye-catching packaging. Brand owners can learn to find differentiation and incremental growth in everyday small scenarios.
2. Brand trust is a lifeline: The red yeast rice incident led to product recalls and profit damage. Even after two and a half years, about 520 victims still require compensation. The company has been forced to make restoring consumer trust a top priority and plans to invest 30 billion yen each in R&D and equipment over the next three years to strengthen quality and safety. Brand owners should recognize that once quality and safety fail, the cost of recovery is enormous.
3. Channel and cost risks: Drugstore channels in Japan are consolidating, consumers are increasingly relying on third-party e-commerce platforms, and rising costs of packaging materials such as bottles and films as well as petrochemical feedstocks are expected to reduce full-year operating profit by 2 billion yen. Brand owners should diversify channel coverage in advance, optimize product portfolios and sales systems, and watch shifts in consumer demand caused by a declining birthrate and an aging population.
Overall: The Kobayashi Pharmaceutical case serves as a risk warning for sellers in the supplement and Japanese drugstore beauty categories, while also pointing to opportunities in product selection and channels.
1. Risk reminders: The red yeast rice supplement scandal caused consumer health damage and a collapse of brand trust. Kobayashi's existing product sales were affected by about 18.4 billion yen in total due to recalls and suspended advertising, and it booked special losses of about 16.3 billion yen related to red yeast rice. Sellers offering similar products must prioritize quality and compliance to avoid huge losses caused by upstream safety problems.
2. Demand shifts and opportunities: A recovery in spending by visitors to Japan once supported Kobayashi's domestic sales, while mainland China and Hong Kong accounted for about 8% of its total revenue. As Japanese-style convenience stores expand, small-packaged daily necessities still enjoy stable demand, but consumers are increasingly accustomed to ordering on third-party e-commerce platforms. Sellers should seize e-commerce channels and monitor changes in the distribution landscape caused by drugstore consolidation in Japan.
3. Crisis response and takeaways: Kobayashi plans to cut about 25% of its SKUs domestically and overseas, and to sell stakes in overseas subsidiaries and external listed companies to optimize capital allocation. Sellers can learn from its approach of focusing on core products and shrinking non-core businesses, while also paying attention to cost pressure from raw material price increases and adjusting procurement and pricing strategies in a timely manner.
Overall: Kobayashi's asset-light model and its response to costs and quality offer several lessons for factories in understanding customer needs and adjusting their own capabilities.
1. OEM and partnership opportunities: Kobayashi outsources part of its production, giving factories the opportunity to become OEM partners for such brands. However, as the brand cuts about 25% of its SKUs, OEM demand will change accordingly. Factories need to improve production flexibility and capabilities for high-mix, small-batch production.
2. Material and cost pressures: Affected by Middle East tensions, packaging materials such as bottles and films, as well as petrochemical raw materials including alcohol and surfactants, have risen in price. Kobayashi expects full-year operating profit to decrease by 2 billion yen as a result. Factories should monitor upstream raw material price fluctuations, negotiate cost-sharing mechanisms with customers, and reduce overall costs through packaging and process improvements.
3. Quality and safety, and equipment investment: After the red yeast rice incident, Kobayashi plans to invest 30 billion yen each in R&D and equipment over the next three years to strengthen quality and safety. This reminds factories to build strict quality traceability and testing systems, meet customers' high requirements for compliance and safety as much as possible, and upgrade equipment when appropriate to take on higher-quality orders.
Overall: The collapse of trust, rising costs, and weakening distribution channels confronting Kobayashi highlight typical pain points of established Japanese consumer brands and point to clear service opportunities for providers.
1. Industry trends and client pain points: The supplement scandal has driven down both earnings and trust, with external shareholders repeatedly pressing for change. At the same time, raw material costs have risen, domestic drugstore channels are consolidating, and consumers are shifting to third-party e-commerce platforms, all hindering traditional sales systems. Service providers can offer consulting and operational support for brand rebuilding, channel transformation, and cost control.
2. Demand for solutions: Kobayashi has made restoring consumer trust a top priority, planned to invest 30 billion yen each in R&D and equipment over three years to strengthen quality and safety, while cutting roughly 25% of SKUs and selling non-core assets to optimize capital allocation. These actions require professional support in areas such as product portfolio rationalization, quality and compliance system building, and supply-chain cost reduction.
3. Capital and governance services: Private equity firms CVC and NSSK have proposed a privatization acquisition worth more than 500 billion yen, so the company needs financial advisory, legal, and transaction structuring support. Activist investor Oasis Management has also pushed governance reforms through shareholder proposals and litigation, underscoring the service demand for listed companies in dealing with activist shareholders and improving governance.
Overall: Kobayashi's channel shifts and business difficulties show that brands are becoming more reliant on third-party e-commerce platforms, giving marketplace operators clear entry points for merchant recruitment and operations.
1. Brands shifting channels online: The article notes that domestic drugstore channels are consolidating, consumers are accustomed to ordering on third-party e-commerce platforms, and Kobayashi's product portfolio and sales system urgently need restructuring. Marketplace operators can strengthen recruitment of Japanese drugstore and daily-goods brands, provide online operating tools and traffic entry points, and help brands reach new consumer groups.
2. Helping brands optimize product assortments: Kobayashi is planning to cut about 25% of its SKUs at home and overseas to ease cost pressure and resource fragmentation. Marketplace operators can use sales data and analytics to help brands identify efficient items and phase out inefficient long-tail products, improving the operating efficiency of e-commerce channels.
3. Risk avoidance and trust building: Because Kobayashi experienced the red yeast rice incident, marketplace operators should pay more attention to reviewing the quality records and compliance qualifications of similar brands when onboarding them, and help rebuild consumer trust through quality labels, after-sales guarantees, and user review mechanisms, thereby reducing reputational risk for the platform itself.
Overall: Kobayashi's trajectory from a "Japanese miracle drug" maker to a company facing privatization provides a typical case study for researching the difficulties of established Japanese pharmaceutical companies, family business governance, and industrial transformation.
1. New industry dynamics: Since 2024, Taisho Pharmaceutical and Hisamitsu Pharmaceutical have both been taken private voluntarily by their founding families; both are family businesses with more than a century of history. Kobayashi, meanwhile, has received an acquisition proposal amid declining earnings and shareholder pressure. This reflects that the golden age of established Japanese drugmakers has passed, and exiting public markets to escape short-term earnings pressure and invest in long-term strategy is becoming a wave.
2. New issues and policy/regulatory implications: The red yeast rice supplement incident caused consumer health damage and even deaths. By August 2026, about 520 people had been certified as eligible for compensation, and Kobayashi was forced to exit the red yeast rice business. The incident highlights the importance of raw material safety, quality traceability, victim compensation mechanisms, and crisis regulation of listed companies, and can serve as a reference for other countries improving relevant regulations.
3. Business model and governance research: With its "fishing for big fish in a small pond" niche market strategy, Kobayashi maintained net profit growth for 26 consecutive fiscal years. But the red yeast rice incident exposed weaknesses in internal quality control and founding-family governance. Activist investor Oasis Management's pressure through shareholder proposals and litigation also highlights the research value of checks and balances and board independence in family businesses.
Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .